Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZVRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZevra sells AZSTARYS portfolio to Commave for $50M, repays $63M debt facility in full
Filed March 16, 2026 · Period ending March 12, 2026 · ~1 min read
Key Changes
-
high
Zevra sold its SDX portfolio including AZSTARYS and KP1077 to Commave for $50M cash ($25M upfront, $20M within 10 days, $5M upon records delivery), settling Delaware litigation and terminating their 2019 license agreement.
Item 1.01 verify on EDGAR → -
high
Company repaid entire $63M senior secured loan facility on March 12, three years early, terminating the Credit Agreement and releasing all liens on substantially all company and subsidiary assets.
Item 1.02 verify on EDGAR → -
medium
Parties agreed to dismiss Delaware litigation with prejudice within three business days and provided mutual releases for all claims related to the AZSTARYS License Agreement.
Item 1.01 verify on EDGAR → -
medium
Zevra granted Commave a perpetual, royalty-free, worldwide license to any SDX-related patents and know-how retained by Zevra, ensuring no future IP disputes or royalty obligations.
Item 1.01 verify on EDGAR →
Summary
Zevra Therapeutics executed a major portfolio restructuring, divesting its AZSTARYS ADHD treatment and related SDX assets to Commave for $50 million while simultaneously eliminating $63 million in secured debt.
The $50M proceeds likely funded the early debt repayment, which removes liens on company assets and eliminates interest obligations three years ahead of the 2029 maturity date. For retail investors, this represents a strategic pivot away from the AZSTARYS franchise, converting a revenue-generating asset into cash while de-risking the balance sheet.
The company now has greater financial flexibility without debt covenants or encumbered assets, but has divested a commercial-stage product. Watch for management's next steps: whether they deploy the net proceeds toward their remaining pipeline, return capital to shareholders, or pursue new business development opportunities. The Q1 2026 earnings call should clarify the strategic rationale and forward revenue guidance without AZSTARYS.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Collaboration and License Agreement between the parties dated September 3, 2019, as amended (the “AZSTARYS License Agreement”).
Zevra entered into an agreement with Commave to sell assets and settle pending Delaware litigation. The litigation involved claims under their 2019 collaboration and license agreement for AZSTARYS. This resolves a legal dispute while divesting key assets.
Added in current filing · verify on EDGAR →
In addition, under the Agreement, the Company and Commave have agreed to terminate the AZSTARYS License Agreement in its entirety, and each party has released the other from any and all claims for any acts or omissions arising prior to or as of the effective date of the Agreement related to or arising from the claims asserted in the Litigation or the AZSTARYS License Agreement.
The parties terminated their AZSTARYS License Agreement completely and provided mutual releases for all claims related to the litigation and license agreement. This provides a clean break and eliminates future liability exposure from the prior relationship.
Added in current filing · verify on EDGAR →
Within three business days following the effective date of the Agreement, the parties are required to file a stipulation of dismissal with prejudice of the Litigation with the Court of Chancery of the State of Delaware.
The parties must file to dismiss the Delaware litigation with prejudice within three business days. Dismissal with prejudice means the claims cannot be refiled, providing finality to the legal dispute.
Event · Item 1.02 — Termination of a Material Definitive Agreement
Item 1.02 — Termination of a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”).
The company fully repaid its senior secured loan facility on March 12, 2026, eliminating approximately $63 million in debt obligations (including $3 million in accrued paid-in-kind interest). This voluntary repayment occurred three years ahead of the April 5, 2029 maturity date.
Added in current filing · verify on EDGAR →
Upon repayment, the Credit Agreement and all related loan documents were terminated, and all liens and security interests granted thereunder on substantially all of the Company's and certain of its subsidiaries' current and future assets were released.
With the debt repayment, all liens and security interests on substantially all company and subsidiary assets have been released. This removes encumbrances that previously secured the $100 million loan facility and provides the company greater financial flexibility.
Added in current filing · verify on EDGAR →
The Credit Agreement provided for a senior secured loan facility in an aggregate principal amount of up to $100.0 million, of which $60.0 million was funded on April 5, 2024.
The terminated facility had a maximum capacity of $100 million, with $60 million initially drawn in April 2024. The repaid amount of approximately $63 million reflects the original principal plus accumulated paid-in-kind interest over the roughly two-year period.
Event · Item 7.01 — Regulation FD Disclosure
Zevra issued a press release announcing an agreement, disclosed under Regulation FD.
Added in current filing · verify on EDGAR →
On March 16, 2026, the Company issued a press release announcing the Agreement. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
The company disclosed an agreement via press release under Regulation FD. The 8-K references the agreement but does not provide details in the body text; the actual terms and nature of the agreement are contained in Exhibit 99.1, which is not included in this filing excerpt.
Event · Item 9.01 — Financial Statements and Exhibits
Zevra Therapeutics filed an 8-K attaching a press release dated March 16, 2026; no material event details disclosed in the filing body.
Added in current filing · view on EDGAR →
99.1 Press Release dated March 16, 2026
The 8-K references a press release dated March 16, 2026, attached as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature and materiality of the event cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify